Leveraging drug conjugate technology to selectively deliver medicine to regenerate bone
Latest News
| 09.04.21 | Bob Ward joins Mesentech's Board of Directors |
| 10.03.21 | New article "Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions" |
| 26.02.21 | New article "Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta" |
| 12.15.20 | Webinar on Duchenne muscular dystrophy bone health is now available online |
| 11.17.20 | David C. Dvorak joins Mesentech's Board of Directors |
| 11.17.20 | Barbara Yanni joins Mesentech's Board of Directors |
| 11.10.20 | CureDuchenne Ventures, and Charles H. Hood Foundation invest in Mesentech for development of Novel Duchenne Muscular Dystrophy Therapy |
Leveraging drug conjugate technology to selectively deliver medicine to regenerate bone
Latest News
| 09.04.21 | Bob Ward joins Mesentech's Board of Directors |
| 10.03.21 | New article "Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions" |
| 26.02.21 | New article "Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta" |
| 12.15.20 | Webinar on Duchenne muscular dystrophy bone health is now available online |
| 11.17.20 | David C. Dvorak joins Mesentech's Board of Directors |
| 11.17.20 | Barbara Yanni joins Mesentech's Board of Directors |
| 11.10.20 | CureDuchenne Ventures, and Charles H. Hood Foundation invest in Mesentech for development of Novel Duchenne Muscular Dystrophy Therapy |
